What question did this study set out to answer?

This study aims to evaluate the effectiveness of lenalidomide maintenance therapy in improving progression-free survival in patients with primary central nervous system lymphoma who are ineligible for consolidative therapies.

June 20, 2026HaematologicaOpen Access

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma

View Full Paper

Ask AI

Bookmark

Authors

JLJi Yun LeeNew Generation University College SKSang‐A KimSeoul National University Bundang Hospital DYDeok-Hwan YangChonnam National University Hwasun Hospital

Discussion

Member takes

Implication

Phase II trial evaluates lenalidomide for improving outcomes in consolidation-ineligible PCNSL, suggesting potential benefits.

Key Points

This study aims to evaluate the effectiveness of lenalidomide maintenance therapy in improving progression-free survival in patients with primary central nervous system lymphoma who are ineligible for consolidative therapies.
Conducted as a multicenter phase II trial with 31 enrolled patients, median age 72 years.
Patients received 15 mg lenalidomide orally on days 1-21 of 28-day cycles for up to 12 cycles after achieving partial response to induction therapy.
Primary endpoint measured was 2-year progression-free survival from initiation of maintenance therapy.
The 2-year progression-free survival was 58.8% (95% CI, 43.4-79.8%), exceeding the threshold of 55% but not statistically significant (p = 0.084).
The 2-year overall survival rate was 83.9%.
53.3% of patients experienced grade 3-4 neutropenia, with treatment discontinued for toxicity in 13% of cases.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a3632d2db0793dc1a53944d https://doi.org/10.3324/haematol.2026.300790

View Full Paper

Ask AI

Bookmark

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider